Mini Review
Volume 13:01, 2024

Malaria Control and Elimination

ISSN: 2470-6965 Open Access

Advancements in G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria

Anna Markiewicz*

Department of Ophthalmology, Jagiellonian University, Kopernika Str. 38, 31-501 Krakow, Poland

Abstract

Glucose-6-phosphate dehydrogenase deficiency presents a significant challenge in the treatment of vivax malaria, as the standard therapy, primaquine, can induce severe hemolysis in affected individuals. This review explores the current landscape of G6PD deficiency testing and its implications for radical cure treatment in vivax malaria. While traditional laboratory-based tests have been the gold standard, recent advancements in point-of-care testing offer rapid and accurate results, overcoming many barriers to accessibility. Technologies such as lateral flow assays and quantitative G6PD assays provide real-time insights into enzyme deficiency, aiding in personalized treatment decisions. Moreover, molecular diagnostics, including next-generation sequencing offer valuable genetic information for risk stratification and genetic counseling. Despite these advancements, challenges in implementing these technologies persist, particularly in resource-limited settings. Collaborative efforts are essential to address these challenges and optimize the management of vivax malaria in G6PD-deficient populations, contributing to global malaria elimination efforts.

Keywords: Enzyme deficiency • Malaria • Therapy

Introduction

Glucose-6-phosphate dehydrogenase deficiency is an inherited enzymatic disorder that affects more than 400 million people worldwide. Individuals with this deficiency are at risk of developing hemolytic anemia when exposed to certain triggers such as certain foods, infections, and medications. This condition has significant implications, particularly in the context of malaria treatment, as some antimalarial drugs can induce hemolysis in G6PD-deficient individuals. Among the various types of malaria, Plasmodium vivax poses a unique challenge due to its ability to relapse from dormant liver stages, necessitating a radical cure treatment regimen that targets both the blood and liver stages of the parasite. This article explores the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria [1].

Literature Review

Radical cure treatment for vivax malaria involves eliminating both the blood-stage and dormant liver-stage parasites. While drugs like chloroquine and artemisinin-based combination therapies are effective against the blood-stage parasites, primaquine is the only widely available drug effective against the dormant liver-stage parasites. However, primaquine can induce hemolysis in individuals with G6PD deficiency, leading to severe complications. Therefore, accurate G6PD deficiency testing is crucial before administering primaquine to vivax malaria patients to ensure their safety and optimize treatment outcomes. Historically, G6PD deficiency testing has faced several challenges, including limited availability, high cost, and the requirement for specialized equipment and expertise. Traditional laboratory-based tests such as the fluorescent spot test and quantitative enzyme assays have been the gold standard but may not be feasible in resource-limited settings where vivax malaria is endemic [2].

***Address for Correspondence:** Anna Markiewicz, Department of Ophthalmology, Jagiellonian University, Kopernika Str. 38, 31-501 Krakow, Poland; E-mail: markiewicz01@gmail.com*

Received: 02 January, 2024, Manuscript No. mcce-24-130018; **Editor Assigned:** 05 January, 2024, PreQC No. P-130018; **Reviewed:** 16 January, 2024, QC No. Q-130018; **Revised:** 22 January, 2024, Manuscript No. R-130018; **Published:** 29 January, 2024, DOI: 10.37421/2470-6965.2024.13.259

Discussion

Additionally, these tests may not provide immediate results, delaying treatment initiation and potentially compromising patient outcomes. Recent advancements in Point-Of-Care Testing (POCT) technologies have addressed many of the challenges associated with G6PD deficiency testing. POCT devices offer rapid and accurate results at the point of care, enabling healthcare providers to make informed treatment decisions in real-time. One example is the use of lateral flow assays, which can detect G6PD deficiency using a small blood sample within minutes. These tests are portable, affordable, and require minimal training to operate, making them suitable for use in remote and resource-limited settings where vivax malaria is prevalent. Another promising advancement is the development of quantitative G6PD assays that provide a more precise measurement of enzyme activity compared to qualitative tests. These assays utilize spectrophotometry or other biochemical methods to quantify G6PD enzyme levels, allowing for better stratification of G6PD-deficient individuals based on the severity of their deficiency. This information is crucial for determining the appropriate primaquine dosage or alternative treatment options for vivax malaria patients. Furthermore, advancements in molecular diagnostics have enabled the identification of specific G6PD gene mutations associated with enzyme deficiency [3].

Next-generation sequencing techniques can rapidly sequence the G6PD gene and identify known variants, providing valuable genetic information that can inform treatment decisions and genetic counseling for individuals with G6PD deficiency. Despite the advancements in G6PD deficiency testing, several challenges remain in implementing these technologies in routine clinical practice, particularly in low-resource settings. Issues such as cost, infrastructure requirements, and the need for training and quality assurance programs need to be addressed to ensure equitable access to G6PD testing for all vivax malaria patients. Future research should focus on improving the accuracy and affordability of G6PD testing technologies, as well as evaluating their performance in diverse settings and populations. Additionally, efforts to develop safer and more effective alternative treatments for vivax malaria, particularly for individuals with G6PD deficiency, are warranted. Collaborative initiatives involving researchers, healthcare providers, policymakers, and community stakeholders are essential to address these challenges and optimize the management of vivax malaria in G6PD-deficient populations [4-6].

Conclusion

G6PD deficiency testing plays a critical role in guiding radical cure treatment for vivax malaria by identifying individuals at risk of primaquine-induced hemolysis. Recent advancements in point-of-care testing, quantitative assays, and molecular diagnostics have improved the accessibility and accuracy of G6PD testing, paving the way for personalized treatment approaches. However, challenges remain in implementing these technologies in routine clinical practice, particularly in resource-limited settings. Future research and collaborative efforts are needed to overcome these challenges and optimize the management of vivax malaria in G6PD-deficient populations, ultimately contributing to the global effort to eliminate malaria as a public health threat.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Howes, Rosalind E., Katherine E. Battle, Kamini N. Mendis and David L. Smith, et al. "Global epidemiology of *Plasmodium vivax*." *Am J Trop Med Hyg* Suppl 95 (2016):15.
2. Battle, Katherine E., Tim CD Lucas, Michele Nguyen and Rosalind E. Howes, et al. "Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: A spatial and temporal modelling study." *The Lancet* 394 (2019): 332-343.
3. Nguitragool, Wang, Ivo Mueller, Chalermpon Kumpitak and Teerawat Saeseu, et al. "Very high carriage of gametocytes in asymptomatic low-density *Plasmodium falciparum* and P. vivax infections in western Thailand." *Parasites & Vectors* 10 (2017): 1-9.
4. Rovira-Vallbona, Eduard, Juan José Contreras-Mancilla, Roberson Ramirez and Mitchel Guzmán-Guzmán, et al. "Predominance of asymptomatic and sub-microscopic infections characterizes the *Plasmodium gametocyte* reservoir in the Peruvian Amazon." *PLOS Negl Trop Dis* 11 (2017): e0005674.
5. Motshoge, Thato, Grace K. Ababio, Larysa Aleksenko and John Read, et al. "Molecular evidence of high rates of asymptomatic P. vivax infection and very low *P. falciparum* malaria in Botswana." *BMC Infectious Diseases* 16 (2016): 1-8.
6. Almeida, Anne CG, Andrea Kuehn, Arthur JM Castro and Sheila Vitor-Silva, et al. "High proportions of asymptomatic and submicroscopic *Plasmodium vivax* infections in a peri-urban area of low transmission in the Brazilian Amazon." *Parasit Vectors* 11 (2018): 1-13.

How to cite this article: Markiewicz, Anna. “Advancements in G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria.” *Malar Contr Elimination* 13 (2024): 259.